Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.

@article{Ifergan2003ReducedFC,
  title={Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.},
  author={Ilan Ifergan and Issac Meller and Josefin Issakov and Yehuda G Assaraf},
  journal={Cancer},
  year={2003},
  volume={98 9},
  pages={1958-66}
}
BACKGROUND High-dose methotrexate (MTX) is an important component of current protocols for the treatment of osteosarcoma. Although MTX uptake proceeds primarily through the reduced folate carrier (RFC) protein and efflux occurs via multidrug resistance protein 1 (MRP1), RFC protein expression in osteosarcoma remains unexamined. METHODS RFC and MRP1 expression (normalized to beta-actin expression) was examined with Western blot analysis in 11 osteosarcoma specimens obtained at diagnosis and 9… CONTINUE READING

From This Paper

Topics from this paper.
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…